Alle Studien
Aktiv, aber nicht rekrutierendBEOBACHTEND

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

This study is for people with a severe inherited bleeding condition called Type 3 Von Willebrand Disease. If you're already receiving regular treatment (called 'prophylaxis') for this condition, this study might be for you. Researchers want to learn more about how well these treatments work in real life and how they affect your health and quality of life. They will simply observe your usual care for at least 24 weeks, without changing your treatment. This helps us understand what works best and how to improve care for others with Type 3 Von Willebrand Disease.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Sponsor
Hoffmann-La Roche
Einschreibeziel
44
Starten
29. Apr 2025
Geschätzte Fertigstellung
18 Jan 2027

Worum geht es in dieser Studie?

This study is for individuals already diagnosed with a serious inherited bleeding disorder called Type 3 Von Willebrand Disease (VWD). This condition means your blood doesn't clot properly, leading to bleeding problems.

The main goal of this study is to gather information on how effective and safe the treatments you currently receive are. You won't be given any new medicines or asked to change your current treatment. Instead, the study will simply observe what you're already doing with your doctor and how your condition affects your daily life over about six months. This approach helps researchers understand the 'real world' impact of current treatments.

By collecting details about your health and how you feel, the study aims to improve our understanding of Type 3 VWD and how best to manage it. This information can help doctors and researchers find better ways to care for people with this condition in the future. It's a way to learn from those who live with VWD every day.

Wichtige Erkenntnisse

  • Study for people with Type 3 Von Willebrand Disease already on standard treatment.
  • Observes your current care; no new drugs are given.
  • Aims to understand treatment effectiveness and quality of life.
  • Participating will last at least 24 weeks (6 months).
  • Helps improve future care for others with VWD.
  • Your medical care will not be affected if you choose not to participate or withdraw.

Wer könnte berechtigt sein?

To join this study, you must have a confirmed diagnosis of severe Type 3 Von Willebrand Disease. You also need to be receiving your usual, regular treatment (called 'prophylactic therapy') for your condition, typically taking it 1 to 3 times a week, and expect to continue this treatment during the study period. Your blood, liver, and kidney functions should be generally healthy.

There are also some important reasons why you might not be able to join. For example, if you have another bleeding disorder, a recent history of stomach or bowel bleeding, or a history of bleeding in the brain, you wouldn't be suitable. People who have had blood clots or are being treated for them, or those with certain other medical conditions affecting bleeding or clotting, would also not be able to participate.

Additionally, if you are pregnant, planning to become pregnant, or are of childbearing age, you would need to agree to use effective contraception throughout the study. If you're taking certain strong immune-system affecting medications (like systemic immunomodulators), you also wouldn't be able to join, though some specific medications like HIV treatments are exceptions.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Do I have a confirmed diagnosis of Type 3 Von Willebrand Disease?
  2. Am I currently receiving regular (prophylactic) treatment for my VWD?
  3. Am I generally healthy aside from my VWD, with good liver/kidney function?
  4. Have I had any recent stomach/bowel bleeds or bleeds in the brain?
  5. Am I pregnant or planning to become so soon?
  6. Am I generally able to attend appointments without major issues?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, you will continue with your regular medical appointments and treatments as prescribed by your doctor. The study will mainly involve collecting information from your medical records and asking you about your health and quality of life through questionnaires. This will happen over at least 24 weeks (about 6 months).

You won't receive any new medications or treatments specially for the study. Instead, the researchers will observe your usual care. You'll likely have regular check-ups with the study team to record information, but these are typically planned around your existing appointments. There's no strict number of visits mentioned, as it follows your standard care.

Potenzielle Risiken und Vorteile

The main benefit of taking part is contributing valuable information that can help improve care for people with Type 3 Von Willebrand Disease in the future. Since you're receiving your usual care and no new treatments, the direct risks from the study itself are generally low. The risks would be those associated with your ongoing medical condition and its standard treatment. You are always free to leave the study at any time, for any reason, without it affecting your medical care.

Standorte (25)

  • UC Davis
    Verifizierte Postleitzahl
    Sacramento, Vereinigte Staaten
  • University of Minnesota Medical Center
    Verifizierte Postleitzahl
    Minneapolis, Vereinigte Staaten
  • Washington University School of Medicine
    Verifizierte Postleitzahl
    St. Louis, Vereinigte Staaten
  • UZ Leuven Gasthuisberg
    Verifizierte Postleitzahl
    Leuven, Belgien
  • The Hospital for Sick Children
    Verifizierte Postleitzahl
    Toronto, Kanada
  • McGill University Health Center
    Verifizierte Postleitzahl
    Montreal, Kanada
  • IPS SURA Industriales Medellín
    Verifizierte Postleitzahl
    Medellín, Colombia
  • Hopital Claude Huriez - CHU Lille
    Verifizierte Postleitzahl
    Lille, Frankreich
  • Groupe Hospitalier Necker Enfants Malades
    Verifizierte Postleitzahl
    Paris, Frankreich
  • Universitätsklinikum Bonn
    Verifizierte Postleitzahl
    Bonn, Deutschland
  • Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz
    Verifizierte Postleitzahl
    Duisburg, Germany
  • Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin
    Unbestätigt
    Frankfurt/M., Germany

Häufige Fragen

What is Type 3 Von Willebrand Disease?

It's a serious inherited bleeding disorder where your blood doesn't clot properly, leading to increased bleeding.

Wird sich meine Behandlung ändern, wenn ich an dieser Studie teilnehme?

No, you will continue with your current, regular treatment as usual. The study just observes it.

Wie lange werde ich an der Studie teilnehmen?

You will be observed for at least 24 weeks, which is about 6 months.

Do I need to visit the hospital more often for this study?

The study aims to fit around your existing appointments, so you shouldn't have many extra visits.

What kind of information will they collect?

They will collect details from your medical records and ask you questions about your health and how you feel.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.